Actively Recruiting
hUC Mesenchymal Stem Cells (19#iSCLife®-LC) in the Treatment of Decompensated Hepatitis b Cirrhosishepatitis b Cirrhosis
Led by Sclnow Biotechnology Co., Ltd. · Updated on 2026-04-23
20
Participants Needed
1
Research Sites
482 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
1. Evaluation the safety of using human umbilical mesenchymal stem cells to treat patients with hepatitis B cirrhosis. 2. Observe the curative effect of patients with hepatitis B cirrhosis who use human umbilical mesenchymal stem cells to treat. 3. Explore the possible mechanism of human umbilical mesenchymal stem cells to treat patients with hepatitis B cirrhosis.
CONDITIONS
Official Title
hUC Mesenchymal Stem Cells (19#iSCLife®-LC) in the Treatment of Decompensated Hepatitis b Cirrhosishepatitis b Cirrhosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18-60 years old, any gender, with body mass index (BMI) between 19-25 kg/m2 including boundary values
- Diagnosed with hepatitis B cirrhosis according to 2015 AASLD guidelines
- Liver function classified as Child-Pugh B or C with scores between 7-12
- Model for End-Stage Liver Disease score 21 points or less
- No stem cell therapy received in the past 6 months
- Able to provide informed consent following study instructions
You will not qualify if you...
- Insufficiency of vital organs such as heart, kidney, or lung
- End-stage cirrhosis with severe complications like hepatic encephalopathy, gastrointestinal bleeding, severe bleeding tendency, or massive ascites
- Uncontrolled infections such as peritonitis or pneumonia
- History of severe allergic reactions or allergies to two or more kinds of food or medicine
- Positive for HIV or syphilis antibodies
- Alpha fetoprotein level above 400 ng/mL with or without imaging evidence of primary liver cancer
- Liver disease caused by factors other than chronic hepatitis B virus infection
- Severe mental illness or cognitive impairment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Xiangya Hospital Central South University
Changsha, Hunan, China, 410008
Actively Recruiting
Research Team
L
Lei Guo, doctor
CONTACT
X
Xuegong Fan, doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here